Latest filings (excl ownership)
15-12G
Securities registration termination
13 Feb 23
10-Q
2023 Q1
Quarterly report
9 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
POS AM
Prospectus update (post-effective amendment)
2 Feb 23
POS AM
Prospectus update (post-effective amendment)
2 Feb 23
POS AM
Prospectus update (post-effective amendment)
2 Feb 23
POS AM
Prospectus update (post-effective amendment)
2 Feb 23
POS AM
Prospectus update (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
8-K
SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
1 Feb 23
25-NSE
Exchange delisting
31 Jan 23
10-K/A
2022 FY
Annual report (amended)
27 Jan 23
8-K
Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger
12 Dec 22
10-K
2022 FY
Annual report
22 Nov 22
8-K
Meridian Bioscience Reports Fourth Quarter and Full Year Fiscal 2022 Operating Results
22 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
11 Oct 22
DEFA14A
Additional proxy soliciting materials
30 Sep 22
8-K
Other Events
30 Sep 22
DEFM14A
Proxy related to merger
8 Sep 22
PREM14A
Preliminary proxy related to merger
25 Aug 22
10-Q
2022 Q3
Quarterly report
5 Aug 22
8-K
Meridian Bioscience Reports Third Quarter Fiscal 2022 Operating Results
5 Aug 22
8-K
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay
29 Jul 22
DEFA14A
Additional proxy soliciting materials
8 Jul 22
DEFA14A
Additional proxy soliciting materials
7 Jul 22
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13D/A
Magnetar Financial LLC
3 Feb 23
4
Felicia Williams
31 Jan 23
4
Catherine Sazdanoff
31 Jan 23
4
John McCune Jr. Rice
31 Jan 23
4
John McIlwraith
31 Jan 23
4
Dwight E Ellingwood
31 Jan 23
4
Anthony P Bihl III
31 Jan 23
4
James M. Anderson
31 Jan 23
4
John P. Kenny
31 Jan 23
4
Andrew S. Kitzmiller
31 Jan 23
4
LOURDES WELTZIEN
31 Jan 23
4
Tony Serafini-Lamanna
31 Jan 23
4
Julie Diana Smith
31 Jan 23
SC 13G/A
ROYCE & ASSOCIATES LP
31 Jan 23
SC 13G/A
BlackRock Inc.
26 Jan 23
SC 13G/A
BlackRock Inc.
20 Jan 23
SC 13D/A
Magnetar Financial LLC
10 Jan 23
4
James M. Anderson
9 Jan 23
4
Julie Diana Smith
7 Dec 22
SC 13D/A
Magnetar Financial LLC
2 Dec 22
4
Julie Diana Smith
17 Nov 22
4
Tony Serafini-Lamanna
17 Nov 22
4
LOURDES WELTZIEN
17 Nov 22
4
Julie Diana Smith
8 Nov 22
4
LOURDES WELTZIEN
8 Nov 22
4
Tony Serafini-Lamanna
8 Nov 22
4
John P. Kenny
8 Nov 22
SC 13D/A
Magnetar Financial LLC
3 Nov 22
SC 13D/A
Impactive Capital LP
28 Oct 22
SC 13D/A
Impactive Capital LP
18 Oct 22
4
Julie Diana Smith
5 Oct 22
4
Tony Serafini-Lamanna
5 Oct 22
4
John P. Kenny
5 Oct 22
SC 13D/A
Impactive Capital LP
19 Sep 22
SC 13D
Magnetar Financial LLC
19 Sep 22
SC 13D/A
Impactive Capital LP
7 Sep 22
SC 13G/A
EARNEST PARTNERS LLC
10 Aug 22
4
John P. Kenny
28 Jun 22
4
John P. Kenny
24 Jun 22